Literature DB >> 1280230

Spleen protein tyrosine kinases TPK-IIB and CSK display different immunoreactivity and opposite specificities toward c-src-derived peptides.

A M Brunati1, G Allee, O Marin, A Donella-Deana, L Cesaro, C Bougeret, R Fagard, R Benarous, S Fischer, L A Pinna.   

Abstract

Polyclonal antibodies have been raised against two synthetic peptides reproducing the 48-64 and 353-369 sequences of CSK, a protein tyrosine kinase implicated in the down-regulation of src-related protein kinases. Both antibodies specifically recognize recombinant CSK and a CSK-related 49 kDa protein tyrosine kinase present in spleen but they do not cross-react with purified TPK-IIB, a spleen protein tyrosine kinase sharing with CSK catalytic activity toward src kinases and incapability to autophosphorylate. CSK and TPK-IIB once resolved from each other by heparin-Sepharose affinity chromatography, display opposite specificities toward synthetic peptides reproducing the sequences around the main phosphoacceptor residues of pp60c-src, namely Tyr-416 and Tyr-527. These data support the view that TPK-IIB and CSK may exert opposite effects on the activity of src-related protein tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280230     DOI: 10.1016/0014-5793(92)81212-5

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  2 in total

1.  Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity.

Authors:  Arianna Donella-Deana; Luca Cesaro; Stefania Sarno; Maria Ruzzene; Anna Maria Brunati; Oriano Marin; Greg Vilk; Amanda Doherty-Kirby; Gilles Lajoie; David W Litchfield; Lorenzo A Pinna
Journal:  Biochem J       Date:  2003-06-15       Impact factor: 3.857

2.  4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity.

Authors:  E Buchdunger; U Trinks; H Mett; U Regenass; M Müller; T Meyer; E McGlynn; L A Pinna; P Traxler; N B Lydon
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.